eCite Digital Repository

Gefitinib for advanced non-small cell lung cancer

Citation

Sim, EHA and Yang, IA and Wood-Baker, R and Bowman, RV and Fong, KM, Gefitinib for advanced non-small cell lung cancer, Cochrane Database of Systematic Reviews, 2018, (1) Article CD006847. ISSN 1469-493X (2018) [Refereed Article]


Preview
PDF
2Mb
  

Copyright Statement

Copyright 2018 The Cochrane Collaboration.

DOI: doi:10.1002/14651858.CD006847.pub2

Abstract

Background: The role of gefitinib for the treatment of advanced non-small cell lung cancer (NSCLC) is evolving. We undertook a systematic review to evaluate the available evidence from all randomised trials.

Objectives: To determine the effectiveness and safety of gefitinib as first-line, second-line or maintenance treatment for advanced NSCLC.

Search methods: We performed searches in CENTRAL, MEDLINE and Embase from inception to 17 February 2017. We handsearched relevant conference proceedings, clinical trial registries and references lists of retrieved articles.

Selection criteria: We included trials assessing gefitinib, alone or in combination with other treatment, compared to placebo or other treatments in the first- or successive-line treatment of patients with NSCLC, excluding compassionate use.

Data collection and analysis: We used the standard Cochrane methodology. Two authors independently assessed the search results to select those with sound methodological quality. We carried out all analyses on an intention-to-treat basis. We recorded the following outcome data: overall survival, progression-free survival, toxicity, tumour response and quality of life. We also collected data for the following subgroups: Asian ethnicity and positive epidermal growth factor receptor (EGFR) mutation.

Main results: We included 35 eligible randomised controlled trials (RCTs), which examined 12,089 patients.

Item Details

Item Type:Refereed Article
Keywords:getfitnib, non-small lung cancer, NSCLC
Research Division:Medical and Health Sciences
Research Group:Oncology and Carcinogenesis
Research Field:Cancer Therapy (excl. Chemotherapy and Radiation Therapy)
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Cancer and Related Disorders
UTAS Author:Wood-Baker, R (Professor Richard Wood-Baker)
ID Code:130883
Year Published:2018
Web of Science® Times Cited:2
Deposited By:Health Sciences
Deposited On:2019-02-19
Last Modified:2019-09-09
Downloads:77 View Download Statistics

Repository Staff Only: item control page